Engineered for
Retatrutide UK
Retatrutide UK
£80.00
Retatrutide UK
£105.00
Retatrutide UK
£69.00
Retatrutide UK
£129.00
Retatrutide UK
£20.00
Retatrutide UK
£149.99
Retatrutide UK
£170.00
Alluvi Healthcare
Retatrutide – Pre-Filled Pen Evaluation
Part of Alluvi Labs’ ongoing research program into advanced GLP-1 multi-agonist compounds.
This formulation is supplied in controlled batches for laboratory analysis of stability, compound behavior, and injector system performance.
Not for human or veterinary consumption.
of stability, compound behavior, and injector system performance.
Not for human or veterinary consumption.
Track. Dose. Progress.
The Alluvi app supports wellness goals with smart tracking, logging nutrition, monitoring weight, and staying consistent through a modern mobile dashboard.
Recovery Meets Routine
Daily gummy supplements crafted for sleep, stress support, and muscle recovery, for rest and protein for strength, all in a clean, delicious form
Power-Up in a Gummy
A delicious way to fuel your body with protein and creatine—Alluvi Gummy Bears are a quick, convenient solution to stay on top of daily nutrients. No scoops. No shakes. Just results.
No prep. No hassle.
Just precision dosing.
Alluvi pens are supplied ready-to-use—no mixing, no guesswork.
Developed for controlled research applications, each unit features fixed, pre-measured volumes to support consistency and reliability during laboratory evaluation.
Not for human or veterinary consumption.
Proven Data. Backed by Research.
Published studies have investigated GLP-1 multi-agonist compounds under controlled conditions.
Alluvi supplies Retatrutide pens exclusively for laboratory research and development.
Not for human or veterinary consumption.
All figures are derived from third-party published studies and are shown only for academic context. All Alluvi products are supplied strictly for laboratory research purposes.
22.5%
loss in weight using Retatrutide
Reference value drawn from published research on GLP-1 multi-agonist compounds.
Provided strictly as a scientific context.
Clinical Study based on a 600-calorie reduction in daily intake
Participants consumed fewer calories per day without being instructed to diet—driven by decreased appetite and satiety signaling.
Provided strictly as a scientific context.
28%
Reported increased energy levels in trials
Reported value in published research relating to GLP-1 multi-agonist compounds.
Provided strictly as a scientific reference point
18.3 KG
Average weight loss during the clinical trial period of 48 weeks on high-dose retatrutide.
Example data point referenced in peer-reviewed studies for GLP-1 multi-agonists.
Alluvi does not promote or imply medical use of its products.
More than peptides.
A Complete Research Platform.
From research-grade compounds to structured data collection and nutritional analysis, Alluvi provides an integrated system designed for controlled research and development programs.
Not for human or veterinary consumption.
